Nanjing Personal Gene Technology Co.,Ltd. (Personalgene) was established in August 2017, it is a wholly-owned subsidiary of Shanghai Personal Biotechnology Co.,Ltd. Relying on Chinese National Healthcare Data (Nanjing) Center, Personalgene aims at providing professional human genome study, molecular diagnosis and healthcare management services for precision medicine.
The company has established the largest gene sequencing platform in Asia with advanced high-throughput sequencing machines, including 10 Illumina HiSeq X Ten, 20 Illumina Nova Seq 6000 and 10 Single Molecule Real-Time (SMRT) sequencing machine PacBio Sequel. With these equipments, we achieved 52 PB storage computing device configuration capacity and a computing speed at 2340 TPF/s.
Strength of our products is obvious. Since we were established in 2011, Personalbio has become the leading company in intestinal microbial sequencing, genome sequencing and transcriptome sequencing, and has independent research technologies and achievements, obtained over 100 invention patents and software copyrights, several cooperated projects were published in Nature, Lancet and other authoritative journals (sub-journals). In 2017, Personalbio signed the cooperation agreement with Chinese National Women's Federation to execute the female high-risk cancer screening in Shanghai, and Huibei, Henan, Jiangxi and Anhui provinces. Relying on our strengths, Nanjing Personalgene focuses on human genome sequencing and analyzing, particularly on healthcare and medication related products.
Team and members. For technical and management positions, including product management, sales promotion, technical support, bioinformatics analysis and laboratory technician, we are willing to recruit people who have strong background in biomedicine, medical science, laboratory medicine and clinical medicine, or who have relevant work experience.
RNA-seq
Proteomics
Metabolomics
Epigenetics
